Intelligence for Pharma R&D Leaders

Merck: 30+ programs in Phase 3 — scaled R&D without proportional headcount growth.

Pfizer: 32 Phase 3 programs, ~20 pivotal starts planned for 2026, $500M R&D savings target.

Sanofi: 80 clinical-stage projects, 34 in Phase 3/registration. $20B planned investment in manufacturing capacity.

Eli Lilly: reached millions more patients, driven by portfolio of growth medicines. $50B+ revenue target by 2028 with pipeline spanning Alzheimer's, oncology, and immunology.

AstraZeneca: 196 pipeline projects, 19 new molecular entities in late-stage. 20 new medicines expected by 2030, more than half first-in-class.

BMS: 10+ new product launch opportunities by 2030, with "growth portfolio" performance expected to offset legacy declines.

Roche: 100+ clinical-stage assets and 12 late-stage studies replacing biosimilar losses from Avastin, Herceptin, and Rituxan with next-generation personalized medicine.

AbbVie: $100B commitment to U.S. R&D and capital investment over the next decade. Diversified growth platform across immunology, neuroscience, oncology.

Regeneron: four blockbuster medicines driving growth, with "exciting data read-outs and potential approvals in 2026 across a broad range of diseases."

Gilead: 2026 framed as a launch year — two new cancer therapies plus an additional HIV treatment option.

Teva: "Pivot to Growth" strategy delivering three consecutive years of growth, with two-thirds of transformation savings realized by 2026.

By 2030, patents for 190 drugs are likely to expire, putting $236 billion in sales at risk.

77% of labs expect AI within 2 years; only 11% have reached a fully predictive state.

The average pharma company holds 180 days of finished goods inventory. Top performers operate at 100 days.

Control towers deliver 30% inventory-day reduction, 50% faster delivery, and 90% fewer emergency orders.

Biopharma supply chain digitization delivers 50% better risk-sensing, 50% enhanced yields, 48% warehouse efficiency.

74% of FDA Complete Response Letters involved quality/manufacturing issues — 150 out of 202 applications.

Quality problems remain one of the most common reasons for drug shortages. 40% of shortages are demand-driven.

Fewer than 44% of life science supply chains use technology to calculate scenarios.

63% of life sciences leaders rank AI as their top investment area — but lack the infrastructure to act on it.

Novartis: $23B U.S. investment program scaling radioligand therapy manufacturing across multiple new sites.

GSK: $30B U.S. investment program including a new biologics flex factory commencing construction in 2026, expanded AI/digital capabilities, and multiple expected approvals.

Novo Nordisk: demand will outgrow what can be produced — by the company and the competition.

Johnson & Johnson: $55 billion in U.S. manufacturing and technology investment over the next four years.